AzTrials
AzTrials

Obstructive Sleep ApneaNCT02329925

The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea

A study testing Tongue Stabilizing Device (TSD) in people with Obstructive Sleep Apnea, run by University of British Columbia at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. Tongue Stabilizing Device (TSD) is a preformed appliance for Obstructive Sleep Apnea (OSA) that protrudes the tongue and improves upper airway structure and function during… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obstructive Sleep Apnea
What is being tested?
Tongue Stabilizing Device (TSD)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
41 participants
Where
1 siteCanada
Study dates
Jan 2015to May 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients included in this study must:
  • be 18 years of age or older
  • have an objective diagnosis of mild to moderate obstructive sleep apnea (OSA) [5 ≤ AHI ≤ 50]; and
  • have a Body Mass Index (BMI) ≤ 35

Who cannot join

  • Patients are excluded in this study who:
  • have had previous surgery of the soft palate;
  • have neuromuscular disease;
  • are taking medications which disturb sleep; and/or
  • have ≤ 90% oxygen saturation levels for 20% of the night.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • University of British Columbia

    Vancouver, British Columbia, V6T 1Z3

Other trials in Canada

About this study

The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. Tongue Stabilizing Device (TSD) is a preformed appliance for Obstructive Sleep Apnea (OSA) that protrudes the tongue and improves upper airway structure and function during sleep. Investigators will attempt to assess efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing routes in OSA patients during sleep.

Read the detailed description

Purpose:

The purpose of this study is to determine the efficacy of TSD and to assess if it alters swallowing frequency and breathing modes in OSA patients during sleep.

Hypothesis:

Investigators hypothesize that TSD therapy will improve OSA symptoms and will lead to effective nasal breathing which may decrease swallowing frequency in OSA patients during sleep.

Justification:

The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. OSA occurs when there is complete or partial obstruction in the pharynx during sleep which results in an impact on both breathing and swallowing. Continuous Positive Airway Pressure (CPAP) and Oral Appliance (OA) therapy improve breathing in OSA patients, but these therapies have some disadvantages such as poor adherence and expensiveness. TSD is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep. TSD is simpler and more economical than other therapies and may bring similar benefits. In regards to swallowing, it has been reported that swallowing frequency during sleep increases with OSA severity and when preceded by oronasal breathing. However, it still remains to be determined if the treatment of OSA alters breathing modes and swallowing frequency in OSA patients during sleep. An evaluation of the efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing route may be an important step in the sleep medical field so as to understand the mechanism(s) by which TSD therapy improves the clinical condition of OSA.

Objectives:

The objective of this study is to clarify the mechanism(s) by which TSD therapy improves the clinical condition of OSA in terms of regulation of swallowing and breathing modes in OSA patients during sleep.

Research Methods:

Investigators plan to collect data from a minimum of 60 patients who have been diagnosed with OSA .In addition to the regular sleep study electrodes and measurements, investigators will require four supplementary standard sleep channels that utilize standard sleep recording tools. Breathing modes (pure nasal, oral and oro-nasal) will be evaluated with a nasal pressure transducer, which is traditionally used for patients' evaluation (Braebon) and an additional standard oral flow thermistor sensor (1) (Braebon). The degree of mouth opening will be scored with a jaw sensor® (2). Swallowing will be scored based on a combination of measurements which include laryngeal movements as recorded over the thyroid cartilage with a standard piezoelectric sensor (Opti-Flex, Newlife Technologies, Midlothian, VA, USA) (3), and a sub-mental(SupraHyoid) EMG used for the muscle activity of swallowing (4). Standard polysomnography (PSG) data will be analyzed manually according to AASM criteria by sleep technologists. After regular scoring and sleep evaluation, data from results of the sleep study will be transferred to a CD and one of the authors, Kentaro Okuno, will perform further analysis outside of the laboratory. Using the completed data for sleep stages, apnea and hypopnea events, the swallowing events and breathing modes will be assessed visually and scored. Each epoch will then be evaluated for temporal relation between breathing modes and swallowing as well as for degree of mouth opening, apneas, hypopneas, and arousals. The efficacy endpoint is the change in AHI between baseline and TSD. The polysomnographic results will be subjected to paired Student's t-Tests to demonstrate and difference between baseline and TSD.

Being tested
Tongue Stabilizing Device (TSD)
Medical subject headings
Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tongue Stabilizing Device (TSD)Device

    Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.

Study groups in NCT02329925
Study groupRoleWhat they receive
Tongue Stabilizing Device TreatmentExperimentalTongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Receives: Device: Tongue Stabilizing Device (TSD)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Apnea-hypopnea index

    Measuring apnea-hypopnea index (events/hour) to measure intervention efficacy (e.g. AHI)

    Measured: At baseline

  2. Apnea-hypopnea index

    Measuring changes in apnea-hypopnea index (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.

    Measured: At 2-6 months of TSD treatment follow up

  3. Frequency of swallowing

    Measuring frequency of swallowing (events/hour) to assess influence by intervention

    Measured: At baseline

  4. Frequency of swallowing

    Measuring changes in frequency of swallowing (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.

    Measured: At 2-6 months of TSD treatment follow up

Secondary outcomes (11)
  1. Functional Outcomes of Sleep Questionnaire (FOSQ) responses

    Measuring Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.

    Measured: At baseline

  2. Functional Outcomes of Sleep Questionnaire (FOSQ) responses

    Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to compare baseline and 2-6 months of TSD treatment follow up

    Measured: At 2-6 months of TSD treatment follow up

  3. Epworth Sleepiness Scale (ESS) questionnaire responses.

    Measuring responses to Epworth Sleepiness Scale (ESS) Questionnaire to assess daytime sleepiness.

    Measured: At baseline

  4. Epworth Sleepiness Scale (ESS) questionnaire responses.

    Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare baseline and 2-6 months of TSD treatment follow up

    Measured: At 2-6 months of TSD treatment follow up

  5. VR-36 survey responses

    Measuring VR-36 survey responses which assesses general health status.

    Measured: At baseline

  6. VR-36 survey responses

    Measuring changes in VR-36 survey responses to compare baseline and 2-6 months of TSD treatment follow up

    Measured: At 2-6 months of TSD treatment follow up

  7. Breathing route

    Measuring breathing route to assess influence by intervention

    Measured: At baseline

  8. Breathing route

    Measuring changes in breathing route to compare baseline and 2-6 months of TSD treatment follow up

    Measured: At 2-6 months of TSD treatment follow up

  9. Swallowing apnea time

    Measuring swallowing apnea time (sec) to assess influence by intervention

    Measured: At baseline

  10. Swallowing apnea time

    Measuring changes in swallowing apnea time (sec) to compare baseline and 2-6 months of TSD treatment follow up

    Measured: At 2-6 months of TSD treatment follow up

  11. Compliance (Measuring adherence (hours/nights and nights/week of intervention use))

    Measuring adherence (hours/nights and nights/week of intervention use)

    Measured: At 2-6 months of TSD treatment follow up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jan 2015 (estimated)
  2. Study startJan 2015
  3. Primary completionMay 2019
  4. Study completionMay 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
41 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02329925
Sponsor's protocol ID
H14-01333
Status last verified
Nov 2022
First submitted
12 Dec 2014
Last updated
30 Nov 2022
Results posted
No
Data monitoring committee
No

Publications

  • Alshhrani WM, Hamoda MM, Okuno K, Kohzuka Y, Fleetham JA, Ayas NT, Comey R, Almeida FR. The efficacy of a titrated tongue-stabilizing device on obstructive sleep apnea: a quasi-experimental study. J Clin Sleep Med. 2021 Aug 1;17(8):1607-1618. doi: 10.5664/jcsm.9260.

    PubMed 33745505

Questions about this trial

What is this clinical trial studying?

A study testing Tongue Stabilizing Device (TSD) in people with Obstructive Sleep Apnea, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Apnea-hypopnea index (time frame: At baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02329925, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in